Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for men ...

It has been about a month since the last earnings report for AtaiBeckley Inc (ATAI). Shares have added about 0.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

Atai's lead candidate, BPL-003, is an intranasal formulation that's being tested in a phase 3 trial for adults with treatment-resistant depression, which is defined as inadequate response to at least ...

Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies. The pharma giant said the acquisition ...

Atai Life Sciences, a clinical-stage biopharmaceutical company focused on mental health treatments, announced the completion of a public offering on February 14, 2025, raising approximately $63.25 ...

Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders. ATAI's lead asset, BPL-003, ...

On Thursday, Atai announced that it and its clinical partner Beckley Psytech had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for their investigational ...

Atai Life Sciences announced positive results from a Phase 2a study of BPL-003, a synthetic intranasal treatment for alcohol use disorder (AUD), showing that a single dose combined with relapse ...